嗜粘蛋白阿克曼氏菌与心血管及代谢性疾病相关性的研究进展

doi:10.12122/j.issn.1673-4254.2026.02.25

摘要/Abstract

摘要：

心血管疾病（CVD）是全球主要的死亡原因之一，具有高发病率和死亡率，代谢性疾病是CVD的重要危险因素。近年来，越来越多的研究表明，肠道菌群在代谢性疾病和CVD的发生、发展及病理机制中扮演着重要角色。嗜黏蛋白阿克曼菌（A.muciniphila）是一种有潜力的二代益生菌，因其独特的代谢功能和免疫调节特性而备受关注。本文系统阐述A. muciniphila通过改善肠道屏障功能、调节脂质与葡萄糖代谢、增加短链脂肪酸生成、抑制炎症反应等多种途径，对代谢性疾病产生积极影响。同时，A. muciniphila也参与抗动脉粥样硬化、血压调控、减轻心房颤动和肺动脉高压等心血管保护过程，其机制涉及免疫调节、代谢物调控及肠道-心血管轴的多重交互，为相关疾病的干预提供了新的微生物靶点与策略。

关键词: 嗜黏蛋白阿克曼菌, 肠道菌群, 代谢性疾病, 心血管疾病

Abstract:

Cardiovascular disease (CVD) is one of the leading causes of death globally, characterized by high morbidity and mortality rates. Metabolic disorders are critical risk factors for CVD. In recent years, growing evidence has highlighted the crucial role of gut microbiota in the onset, progression, and pathological mechanisms of both metabolic diseases and CVD. Akkermansia muciniphila (A. muciniphila), a promising next-generation probiotic, has attracted considerable attention due to its unique metabolic functions and immunomodulatory properties. This review systematically summarizes the mechanisms and research progress regarding the role of A. muciniphila in metabolic diseases and cardiovascular diseases. It elucidates how this bacterium exerts beneficial effects on metabolic disorders through multiple pathways, including improving gut barrier function, regulating lipid and glucose metabolism, increasing short-chain fatty acid production, and suppressing inflammatory responses. Meanwhile, A. muciniphila is also involved in cardiovascular protective processes such as anti-atherosclerosis, blood pressure regulation, alleviation of atrial fibrillation, and improvement of pulmonary arterial hypertension. Its mechanisms involve immunomodulation, regulation of metabolites, and multi-level interactions along the gut-cardiovascular axis, offering novel microbial targets and strategies for intervening in related diseases.

Key words: Akkermansia muciniphila, gut Microbiota, metabolic disease, cardiovascular diseases

姜思捷, 宫澜, 郑华. 嗜粘蛋白阿克曼氏菌与心血管及代谢性疾病相关性的研究进展[J]. 南方医科大学学报, 2026, 46(2): 473-478.

Sijie JIANG, Lan GONG, Hua ZHENG. Research progress on the correlation between Akkermansia muciniphila and cardiovascular diseases[J]. Journal of Southern Medical University, 2026, 46(2): 473-478.

图/表 2

参考文献 51

[1]	Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study[J]. Lancet, 2020, 395(10226): 795-808. doi：10.1016/s0140-6736(19)32008-2
[2]	刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国全科医学, 2025, 28(1): 20-38.
[3]	Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association[J]. Circulation, 2022, 145(8): e153-639.
[4]	Bansal A, Hiwale K. Updates in the management of coronary artery disease: a review article[J]. Cureus, 2023, 15(12): e50644.
[5]	沙珊珊, 董世荣, 杨玉菊. 肠道菌群及代谢物调控宿主肠道免疫的研究进展[J]. 生物技术通报, 2023, 39(8): 126-36.
[6]	de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights[J]. Gut, 2022, 71(5): 1020-32. doi：10.1136/gutjnl-2021-326789
[7]	Zou YF, Song XJ, Liu N, et al. Intestinal flora: a potential new regulator of cardiovascular disease[J]. Aging Dis, 2022, 13(3): 753-72. doi：10.14336/ad.2021.1022
[8]	Zhao YQ, Yang HJ, Wu P, et al. Akkermansia muciniphila: a promising probiotic against inflammation and metabolic disorders[J]. Virulence, 2024, 15(1): 2375555. doi：10.1080/21505594.2024.2375555
[9]	Xiao X, Wu YY, Jie ZY, et al. Akkermansia Muciniphila supplementation improves hyperlipidemia, cardiac function, and gut microbiota in high fat fed apolipoprotein E-deficient mice[J]. Prostaglandins Other Lipid Mediat, 2024, 175: 106906. doi：10.1016/j.prostaglandins.2024.106906
[10]	Al Samarraie A, Pichette M, Rousseau G. Role of the gut microbiome in the development of atherosclerotic cardiovascular disease[J]. Int J Mol Sci, 2023, 24(6): 5420. doi：10.3390/ijms24065420
[11]	Gofron K, Berezowski A, Gofron M, et al. Akkermansia muciniphila -impact on the cardiovascular risk, the intestine inflammation and obesity[J]. Acta Biochim Pol, 2024, 71: 13550. doi：10.3389/abp.2024.13550
[12]	Depommier C, Van Hul M, Everard A, et al. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice[J]. Gut Microbes, 2020, 11(5): 1231-45. doi：10.1080/19490976.2020.1737307
[13]	Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity[J]. Proc Natl Acad Sci USA, 2013, 110(22): 9066-71. doi：10.1073/pnas.1219451110
[14]	Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study[J]. Nat Med, 2019, 25(7): 1096-103. doi：10.1038/s41591-019-0495-2
[15]	Liu JQ, Liu YH, Huang CQ, et al. Quercetin-driven Akkermansia muciniphila alleviates obesity by modulating bile acid metabolism via an ILA/m⁶A/CYP8B1 signaling[J]. Adv Sci (Weinh), 2025, 12(12): e2412865. doi：10.1002/advs.202412865
[16]	Schneeberger M, Everard A, Gómez-Valadés AG, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice[J]. Sci Rep, 2015, 5: 16643. doi：10.1038/srep16643
[17]	Shen J, Tong XD, Sud N, et al. Low-density lipoprotein receptor signaling mediates the triglyceride-lowering action of Akkermansia muciniphila in genetic-induced hyperlipidemia[J]. Arterioscler Thromb Vasc Biol, 2016, 36(7): 1448-56. doi：10.1161/atvbaha.116.307597
[18]	Lukovac S, Belzer C, Pellis L, et al. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids[J]. mBio, 2014, 5(4): e01438-14. doi：10.1128/mbio.01438-14
[19]	Jia BL, Zou YQ, Han X, et al. Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease[J]. Trends Microbiol, 2023, 31(1): 76-91. doi：10.1016/j.tim.2022.08.003
[20]	Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med, 2017, 23(1): 107-13. doi：10.1038/nm.4236
[21]	Zheng XF, Huang WT, Li QB, et al. Membrane protein Amuc_1100 derived from Akkermansia muciniphila facilitates lipolysis and browning via activating the AC3/PKA/HSL pathway[J]. Microbiol Spectr, 2023, 11(2): e0432322. doi：10.1128/spectrum.04323-22
[22]	Zhang W, Xu JH, Yu T, et al. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice[J]. Biomed Pharmacother, 2019, 118: 109131. doi：10.1016/j.biopha.2019.109131
[23]	Thingholm LB, Rühlemann MC, Koch M, et al. Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition[J]. Cell Host Microbe, 2019, 26(2): 252-64.e10. doi：10.1016/j.chom.2019.07.004
[24]	Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2018, 119(1): 105-10. doi：10.1002/jcb.26174
[25]	Bian XY, Wu WR, Yang LY, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice[J]. Front Microbiol, 2019, 10: 2259. doi：10.3389/fmicb.2019.02259
[26]	Liu MN, Zhang L, Dong XY, et al. Effects of Akkermansia muciniphila on the proliferation, apoptosis and insulin secretion of rat islet cell tumor cells[J]. Sichuan da Xue Xue Bao Yi Xue Ban, 2020, 51(1): 13-7.
[27]	谭玥, 毕亚艳. 血清尿酸在心血管疾病中的作用机制研究进展[J]. 疑难病杂志, 2022, 21(1): 90-3.
[28]	张里华, 刘佳秀, 夏效东. 嗜黏蛋白阿克曼氏菌对高尿酸血症小鼠血清尿酸及组织炎症的影响及机制[J]. 食品科学, 2023, 44(5): 121-7.
[29]	Li J, Lin SQ, Vanhoutte PM, et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in apoe^-/- mice[J]. Circulation, 2016, 133(24): 2434-46. doi：10.1161/circulationaha.115.019645
[30]	Reunanen J, Kainulainen V, Huuskonen L, et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer[J]. Appl Environ Microbiol, 2015, 81(11): 3655-62. doi：10.1128/aem.04050-14
[31]	Mulhall H, DiChiara JM, Huck O, et al. Pasteurized Akkermansia muciniphila reduces periodontal and systemic inflammation induced by Porphyromonas gingivalis in lean and obese mice[J]. J Clin Periodontol, 2022, 49(7): 717-29. doi：10.1111/jcpe.13629
[32]	Katiraei S, de Vries MR, Costain AH, et al. Akkermansia muciniphila exerts lipid-lowering and immunomodulatory effects without affecting neointima formation in hyperlipidemic APOE*3-Leiden.CETP mice[J]. Mol Nutr Food Res, 2020, 64(15): e1900732. doi：10.1002/mnfr.201900732
[33]	Kasahara K, Rey FE. The emerging role of gut microbial metabolism on cardiovascular disease[J]. Curr Opin Microbiol, 2019, 50: 64-70. doi：10.1016/j.mib.2019.09.007
[34]	Seldin MM, Meng YH, Qi HX, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor‑κB[J]. J Am Heart Assoc, 2016, 5(2): e002767. doi：10.1161/jaha.115.002767
[35]	Sun S, Lulla A, Sioda M, et al. Gut microbiota composition and blood pressure[J]. Hypertension, 2019, 73(5): 998-1006. doi：10.1161/hypertensionaha.118.12109
[36]	Lakshmanan AP, Murugesan S, Al Khodor S, et al. The potential impact of a probiotic: Akkermansia muciniphila in the regulation of blood pressure: the current facts and evidence[J]. J Transl Med, 2022, 20(1): 430. doi：10.1186/s12967-022-03631-0
[37]	Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions[J]. Microb Pathog, 2017, 106: 171-81. doi：10.1016/j.micpath.2016.02.005
[38]	Martins FL, Bailey MA, Girardi ACC. Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na⁺/H⁺ exchanger isoform 3, renal angiotensin II, and insulin sensitivity[J]. Hypertension, 2020, 76(3): 839-48. doi：10.1161/hypertensionaha.120.14868
[39]	Buford TW, Sun Y, Roberts LM, et al. Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats[J]. Geroscience, 2020, 42(5): 1307-21. doi：10.1007/s11357-020-00196-y
[40]	Robles-Vera I, Toral M, de la Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects[J]. Br J Pharmacol, 2020, 177(9): 2006-23. doi：10.1111/bph.14965
[41]	Catry E, Bindels LB, Tailleux A, et al. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction[J]. Gut, 2018, 67(2): 271-83. doi：10.1136/gutjnl-2016-313316
[42]	Zhao SQ, Liu W, Wang JQ, et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice[J]. J Mol Endocrinol, 2017, 58(1): 1-14. doi：10.1530/jme-16-0054
[43]	Zhou J, Wang DK, Li BG, et al. Relationship between plasma trimethylamine N-oxide levels and renal dysfunction in patients with hypertension[J]. Kidney Blood Press Res, 2021, 46(4): 421-32. doi：10.1159/000513033
[44]	Zhang WQ, Wang YJ, Zhang A, et al. TMA/TMAO in hypertension: novel horizons and potential therapies[J]. J Cardiovasc Transl Res, 2021, 14(6): 1117-24. doi：10.1007/s12265-021-10115-x
[45]	Li J, Zhao FQ, Wang YD, et al. Gut microbiota dysbiosis contributes to the development of hypertension[J]. Microbiome, 2017, 5(1): 14. doi：10.1186/s40168-016-0222-x
[46]	Zuo K, Li J, Li KB, et al. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation[J]. Gigascience, 2019, 8(6): giz058. doi：10.1093/gigascience/giz058
[47]	Liang ZG, Dong ZX, Guo MH, et al. Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation[J]. J Biochem Mol Toxicol, 2019, 33(2): e22246. doi：10.1002/jbt.22246
[48]	Luo YC, Zhang Y, Han XJ, et al. Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis[J]. EBioMedicine, 2022, 82: 104087. doi：10.1016/j.ebiom.2022.104087
[49]	Huang LL, Zhang HD, Liu YJ, et al. The role of gut and airway microbiota in pulmonary arterial hypertension[J]. Front Microbiol, 2022, 13: 929752. doi：10.3389/fmicb.2022.929752
[50]	Bao ZY, Li HM, Zhang SB, et al. Administration of A. muciniphila ameliorates pulmonary arterial hypertension by targeting miR-208a-3p/NOVA1 axis[J]. Acta Pharmacol Sin, 2023, 44(11): 2201-15. doi：10.1038/s41401-023-01126-2
[51]	贾秋瑾, 吕仕超, 张军平. 慢性心力衰竭患者肠道菌群改变的系统评价[J]. 中华心血管病杂志, 2021, 49(10): 1012-9.